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In an attempt to examine whether the inactivation of p16
INK4a is an important early event in the development of sporadic melanoma in vivo, we have systematically analysed 46 uncultured primary cutaneous melanomas. Loss of heterozygosity (LOH) of chromosome region 9p21-22 (where the p16
INK4a resides) was detected in 11 tumours (24%) by PCR-based LOH analyses. Direct sequencing of all three exons of the p16
INK4a gene in these 11 tumours revealed no somatic mutation although germline mutations which have not been reported previously as common polymorphisms were detected in two patients. Further sequencing analyses of the p16
INK4a
gene exon 2 in 19 additional tumours with no evidence of LOH on 9p21-22 identi®ed only one heterozygous C ± 4T mutation at codon 81 altering a proline to a leucine. A sensitive methylation-speci®c PCR assay did not reveal de novo methylation of the 5'CpG island in exon 1 of the p16
INK4a gene in any of the tumours showing 9p21-22 allelic loss or a heterozygous p16 INK4a mutation. Complete loss of p16 INK4a protein, most likely due to homozygous deletion of the p16
INK4a gene, was observed in 6 (15%) out of 39 evaluable cases by immunohistochemical analyses on frozen sections using two dierent anti-p16
INK4a antibodies. The results show that inactivation of p16
INK4a is not as frequent in primary melanoma as has been reported in cell lines, and warrant further search for another tumour suppressor on 9p21-22. This study also emphasizes the importance of examining uncultured primary tumours rather than cell lines to de®ne early events in tumorigenesis.
Keywords: loss of heterozygosity; microsatellites; gene mutation; tumour suppressor gene; immunohistochemistry Cytogenetic studies in melanoma cell lines (reviewed in Fountain et al., 1990) and subsequent studies on loss of heterozygosity (LOH) in uncultured melanoma tumours have shown that the chromosome 9p21-22 region harbours a tumour suppressor gene which may be involved in the initiation of melanoma (Fountain et al., 1992; Healy et al., 1995 Healy et al., , 1996a Holland et al., 1994; Isshiki et al., 1994; Walker et al., 1994; WeaverFeldhaus et al., 1994) . A candidate tumour suppressor gene from this locus is p16
, a inhibitor of cyclindependent kinase 4 and 6, because this gene is frequently mutated or homozygously deleted in melanoma-derived cell lines (Kamb et al., 1994a; Liu et al., 1995; Nobori et al., 1994) and is mutated in the germline of a subset of familial melanoma patients (Hussussian et al., 1994; Kamb et al., 1994b) . However, subsequent studies that examined in vivo tumours have shown that the intragenic mutations of the p16
gene were rare in cases of sporadic melanoma with LOH of 9p21-22 (Flores et al., 1996; Healy et al., 1996b; Ohta et al., 1994 Ohta et al., , 1996 . This discrepancy suggested that frequent p16
INK4a alterations in cell lines are simply tissue culture artifacts, i.e. only melanoma cells with such alterations can be propagated in culture (Flores et al., 1996; Walker et al., 1998) , and that another tumour suppressor gene is a relevant target of LOH at 9p21-22 (Flores et al., 1996; Ohta et al., 1996; Puig et al., 1995 (Cairns et al., 1995) and transcriptional repression by de novo methylation of the CpG island spanning promoter region of the p16
INK4a gene . Therefore, to de®ne whether inactivation of p16
INK4a is an important early event in the development of sporadic melanoma in vivo, a systematical investigation examining all of these dierent mechanisms of p16
INK4a gene inactivation in uncultured tumours is needed.
In this study, we have examined a total of 46 primary cutaneous melanomas excised at Kanazawa University Hospital. DNA was extracted from microdissected frozen sections in 41 cases and from formalin ®xed paran-embedded materials in ®ve cases in which fresh frozen tissue was not available. Control DNA was obtained either from peripheral blood or normal adjacent skin of the corresponding patients.
First, we carried out PCR-based microsatellite LOH analyses as reported previously (Morita et al., 1998) using D9S157, D9S162, IFNA, D9S171, D9S265, D9S259, D9S169, D9S270 and D9S161 (Research Genetics, Huntsville, AL, USA), all mapped to chromosome 9p21-22. Although the reported heterozygosity values of the markers used in this study ranged from 0.61 ± 0.84 (Gyapay et al., 1994) , actual values at each loci in this study were 0.85 (D9S157), 0.31 (D9S162), 0.37 (IFNA), 0.34 (D9S171), 0.70 (D9S265), 0.22 (D9S259), 0.59 (D9S169), 0.46 (D9S270) and 0.46 (D9S161). The low heterozygosity values at many loci examined may be explained by the relatively homogenous ethnic background of the Japanese population. Nonetheless, all cases were informative at least one of these nine microsatellites, and allelic losses were demonstrated in 11 cases ( Figure  1 ). Representative autoradiographs are shown in Figure 2a . LOH was more frequently detected in thick (44.0 mm) primary tumours than in thin (54.0 mm) primary tumours (9/25 vs 2/21; w2=4.40, P=0.036). Although non-acral melanomas tended to show LOH more frequently than acral melanomas, the dierence was not statistically signi®cant (6/18 vs 5/28, P=0.296 by Fisher's exact method). Nine cases (3, 8, 9, 12, 15, 25, 29, 36 and 39) showed allelic loss encompassing p16
INK4a locus (but see below for case 8). In two other cases (14 and 42), whether the loss involved the p16
INK4a locus could not be determined. Healy et al. (1995 Healy et al. ( , 1996a , who carried out allelotype of 41 primary sporadic melanomas (mostly super®cial spreading and nodular melanomas), identi®ed LOH on chromosome 9p using two microsatellite markers D9S162 and D9S171 in 16 (46%) out of 35 informative cases. The lower frequency of LOH in our series compared to the results of Healy et al. (1995 Healy et al. ( , 1996a ) may partly be explained by the dierence of thickness of the tumour examined. All but one tumour examined by Healy et al. (1995) were more than 1 mm thick (and LOH was actually detected in this tumour of 0.8 mm thick), whereas we included six tumours less than 1 mm in thickness. The thinnest tumour in which LOH was detected in our series was 1.3 mm. We have also examined LOH of several other chromosome arms including 10q and 6q which were frequently lost in sporadic melanomas (Healy et al., 1996a) , but have not observed allelic loss in these thin primary tumours less than 1 mm thick (data not shown). The results suggested that LOH of 9p (and other chromosome arms) did not occur in the early evolutional stage of primary melanoma, or alternatively (and more likely), LOH was missed by a technical artifact because dissection of relatively pure tumour cell populations might have been dicult in these thin primary tumours. Another more interesting possibility is that the dierent type of melanoma examined in both studies might be responsible for the dierent frequency of LOH of 9p21-22. More than half of our samples were acral melanomas which are the main type of melanoma in Japanese and dier from other types of melanomas in clinical characteristics (Krementz et al., 1982; Seiji et al., 1979) and in antigenic pro®le (Kageshita et al., 1991) . Although we did not ®nd signi®cant dierence in frequency of LOH between acral and non-acral melanomas in our limited number of cases, the unexpectedly low frequency of allelic loss on chromosome arm 9p in acral melanomas (5/28; 18%) raises the possibility that the genetic pathways to this particular type of melanoma might be dierent from those to non-acral melanomas commonly seen in Caucasians.
Next, we performed direct sequencing of all the three exons of the p16
INK4a gene in all the 11 tumours that showed LOH of 9p21-22. Additional 19 tumours without 9p21-22 LOH were also examined for mutation in exon 2. PCR ampli®cation of each exon followed by automated sequencing was carried out as described previously (Morita et al., 1998) . Intragenic mutations of the p16
INK4a gene were found in exon 2 in three tumours (Figure 2b ). In cases 8 and 25, however, the same base substitutions were also identi®ed in the germline samples. These two patients did not belong to any cancer-prone syndrome kindred including familial melanoma. None of these germline mutations have been reported as common polymorphisms in general population (Foulkes et al., 1997) . Case 8 carried a double mutation in both tumour and blood DNA samples, which would be predicted to lead to a change in both p16 INK4a and p19 ARF protein (Figure 2b ). Subcloning of the PCR products and subsequent sequencing of individually expanded colonies showed that these two mutations were on the same allele. The same double mutation was previously reported in uncultured non-small cell lung cancer (NSCLC) (Nakagawa et al., 1995) . Unfortunately, as a matched normal DNA sample was not examined in that study, whether the mutation was germline or somatic and whether it conferred growth advantage in vivo in the case of NSCLC could not be determined. However, the presence of the identical double mutation in our patient's germline suggests that it may be an The tumour in this case shows both wild-type and mutated sequences at both codons completely identical to germline, strongly suggesting the retention of both alleles at the p16 INK4a locus within the tumour (see text for detail). Case 22 shows a heterozygous C?T mutation that would substitute proline to leucine at codon 81 of p16
INK4a (but would not change p19 ARF ). Case 25 shows a germline mutation that would lead amino acid alteration in both p16
INK4a and p19 ARF proteins. Tumour DNA harbours only a mutated sequence as this tumour is hemizygous at the p16
INK4a locus p16 INK4a in primary melanoma A Fujimoto et al uncommon polymorphism rather than disease-related mutation. The primary tumour from this case showed LOH at D9S157 and D9S265 encompassing the p16 INK4a locus, but the three microsatellite markers in between (D9S162, IFNA and D9S171) were uninformative (Figure 1) . However, sequencing analyses identi®ed both mutant and wild-type p16
INK4a alleles within the tumour. Simultaneous analysis of a lymph node metastasis excised from this patient suggested a double recombination in an early stem line clone at both sides of the p16
INK4a gene between D9S157 and D9S265, thus explaining the retention of both alleles at the p16 INK4a locus in both the primary tumour and the metastasis. The detail of a hypothetical model of clonal evolution in this particular tumour was described in our previous paper (Morita et al., 1998) . Case 25 also had a C to A base substitution in germline that would be predicted to lead a change in both p16
INK4a and p19 ARF ( Figure  2b ). The same mutation has not been reported so far in any in vivo tumours and cell lines. Because of the lack of functional studies to assess the eect of this DNA changes on p16
INK4a and p19 ARF protein function, the signi®cance of this germline base alteration was unknown. However, this might have contributed to the tumour development, because the tumour showed LOH at D9S157, INFA and D9S169 encompassing p16
INK4a locus and was hemizygous for the mutated p16 INK4a gene. Tumour 22 had a heterozygous C to T mutation in codon 81 of p16
INK4a that would convert amino acid proline to leucine (but would not alter p19 ARF ) (Figure 2b ). This tumour was a nodular melanoma developed in the forearm, and the ®nding of C to T transition at dipyrimidine sequence suggested a role of ultraviolet irradiation (Pollock et al., 1995) . The same mutation was previously reported in several melanoma cell lines (Castellano et al., 1997; Hussussian et al., 1994) , and the resultant mutated p16
INK4a protein was shown to lose its ability to bind CDK4 and CDK6 (Castellano et al., 1997; Smith and Hovig, 1996) . However, tumour 22 retained wild-type p16
INK4a allele. If p16
INK4a haploinsuciency is enough for melanoma initiation as suggested by some authors (Flores et al., 1996; Gonzalgo et al., 1997; Reed et al., 1995) , the heterozygous missense mutations might have played an important role in the tumour development. Another heterozygous p16
INK4a mutation was also found in a melanoma cell line that carried a proline to leucine substitution in codon 114 (Castellano et al., 1997) .
The inactivation of the p16 INK4a gene transcription without altering its primary structure by de novo methylation on the CpG island spanning promoter region in exon 1 and its upstream was reported in many (El-Naggar et al., 1997; Gonzalez et al., 1995; Herman et al., 1995; Merlo et al., 1995) , but not all (Schmidt et al., 1997; Shih et al., 1997) human cancers. Because de novo CpG island hypermethylation of the p16
INK4a gene associated with lack of expression of p16
INK4a was mainly found in tumours displaying LOH on 9p INK4a gene by a sensitive methylation-speci®c PCR assay (Herman et al., 1996) employing the CpG WIZ Methylation Assay Kit (Oncor, Gaithersburg, MD, USA). The reliability of this assay for accurate detection of DNA methylation in tumour specimens has been con®rmed in a recent study examining sporadic melanoma (Gonzalgo et al., 1997) . PCR following sodium bisul®te modi®cation was successful in ten out of 12 samples. All the ten samples including case 22 were ampli®ed only with unmethylated primers, and none of the samples were ampli®ed with methylated primers (Figure 3) . No ampli®cation product was generated in two samples (29 and 42) with any primer sets, probably due to the degradation of the DNA samples prior to chemical modi®cation. The results of no hypermethylation of the p16
INK4a gene in our series of sporadic melanoma are in keeping with those recently reported by Gonzalgo et al. (1997) , who examined 30 uncultured sporadic melanomas by several dierent methods and found only three tumours (10%) showing signi®cant levels of methylation.
Finally, homozygous deletion is also an important mechanism of p16 INK4a inactivation (Cairns et al., 1995) . Two recent studies investigating inactivation of the p16
INK4a gene in a large number of melanoma cell lines identi®ed homozygous deletion in 23/38 (61%) and 26/ 60 (46%) lines, respectively (Castellano et al., 1997; Flores et al., 1996) . However, the latter study (Flores et al., 1996) also examined 40 uncultured sporadic melanomas (mostly metastases) for comparison, and Figure 3 Methylation-speci®c PCR assay of the p16
INK4a gene in primary tumours that showed 9p21-22 allelic loss. Agarose gel electrophoresis of four representative cases is shown. Primer sets used for ampli®cation are designated as unmethylated (U), methylated (M), or wild-type (W). Ampli®cation with W primer set indicates incomplete chemical modi®cation. MM, 100 bp molecular size marker; P, positive controls of unmethylated, methylated, and chemically unmodi®ed wild-type DNA, respectively; N, negative controls. All the four samples tested (cases 3, 8, 9 and 12) were ampli®ed only with a set of unmethylated (U) primers found only nine (22%) tumours harbouring homozygous p16 INK4a deletion by Southern blot analyses. Because we did not have enough DNA for Southern analyses, and because PCR-based assays may not be reliable for detecting homozygous deletion due to the contamination of normal tissues into tumour DNA samples (Cairns et al., 1995) , we looked for possible homozygous p16
INK4a deletion by immunohistochemical analysis (Gazzeri et al., 1998; Kinoshita et al., 1996) . To avoid false-negative results, we used two dierent polyclonal anti-p16 antibodies on frozen sections, one against the entire human p16
INK4a protein (PharMingen, San Diego, CA, USA) and the other recognizes the denaturation-resistant epitopes preferentially on the carboxyl-terminus of human p16
INK4a protein (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The antibodies used and immunostaining protocols followed were the same as those reported by Kinoshita et al. (1996) and Gazzeri et al. (1998) . The validity of the immunohistochemical analysis for detecting p16 Figure 4 Immunohistochemical staining of frozen sections with rabbit anti-entire p16
INK4a protein antibody showing homogeneous nuclear staining as well as some non-speci®c cytoplasmic staining in case 30 (a), and no staining of tumour cell nuclei in case 9 (b). Positive stainings in stromal cells serves as internal positive controls. Bar=100 mm INK4a in primary melanoma A Fujimoto et al
